Kishk, S., Helal, M., Gomaa, M., Salama, I., Moustafa, S., Simons, C. (2018). Insights into Novel Drug Targets in Mycobacterium tuberculosis: Where Do We Stand and Where Do We Go from Here?. test, 2(1), 14-21. doi: 10.21608/rpbs.2018.3874.1004
Safaa Kishk; Mohamed A. Helal; Mohamed S. Gomaa; Ismail Salama; Samia Moustafa; Claire Simons. "Insights into Novel Drug Targets in Mycobacterium tuberculosis: Where Do We Stand and Where Do We Go from Here?". test, 2, 1, 2018, 14-21. doi: 10.21608/rpbs.2018.3874.1004
Kishk, S., Helal, M., Gomaa, M., Salama, I., Moustafa, S., Simons, C. (2018). 'Insights into Novel Drug Targets in Mycobacterium tuberculosis: Where Do We Stand and Where Do We Go from Here?', test, 2(1), pp. 14-21. doi: 10.21608/rpbs.2018.3874.1004
Kishk, S., Helal, M., Gomaa, M., Salama, I., Moustafa, S., Simons, C. Insights into Novel Drug Targets in Mycobacterium tuberculosis: Where Do We Stand and Where Do We Go from Here?. test, 2018; 2(1): 14-21. doi: 10.21608/rpbs.2018.3874.1004

Insights into Novel Drug Targets in Mycobacterium tuberculosis: Where Do We Stand and Where Do We Go from Here?

Records of Pharmaceutical and Biomedical Sciences
Article 2, Volume 2, Issue 1, March 2018, Pages 14-21    PDF (739.51 K)
Document Type: Mini-reviews
DOI: 10.21608/rpbs.2018.3874.1004
Authors
Safaa Kishk* 1; Mohamed A. Helal2; Mohamed S. Gomaa3; Ismail Salama3; Samia Moustafa3; Claire Simons4
1a. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt b. School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK
2a. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt c. Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza 12588, Egypt
3a. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt
4b. School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK
Abstract
Tuberculosis (TB) is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS with 6.3 million new cases of TB reported in 2016. TB is an air-borne disease associated with the aerobic bacterium Mycobacterium tuberculosis (Mtb), which mainly infects the lungs. Aerosolization of diseased pulmonary secretions, by coughing, sneezing and speaking, discharge the Mtb bacilli into the atmosphere. Infected aerosol droplet nuclei sized 1-10 μm are largely trapped in the upper nasal passages or are expelled into the pharynx by the mucociliary mechanism of the lower respiratory tract and are harmlessly swallowed and digested. Infected persons may overcome the initial TB infection, resulting in the development of asymptomatic latent TB. About 10% of individuals may develop the active disease after infection; where the bacteria undergo more rapid growth and overcome the host immune system. In cases of multi-drug resistant (MDR) strains, and extreme drug-resistant (XDR) strains, treatment fails, and the bacteria propagate and attack the host, leading to death from systemic infection. Due to the increased spread of TB worldwide, both the academic and industrial communities have initiated intensive research to develop new therapeutics targeting new enzymes such as cytochrome P450s in Mtb.
Keywords
Mycobacterium tuberculosis; Cytochrome P450s; Therapeutics
Statistics
Article View: 628
PDF Download: 564